About 100 reports

  • 2 Type 2 Diabetes (T2D): Executive Summary
  • 12.1 BIBLIOGRAPHY

THE SAFETY AND TOLERABILITY OF GLP-## RECEPTOR AGONISTS IN THE TREATMENT OF TYPE ## DIABETES: A REVIEW.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, 2016 and 2026
  • 2.1 RELATED REPORTS

Comparison of the prevalence of chronic kidney disease in Japanese patients with type ## and type ## diabetes.

  • Type 2 Diabetes
  • Germany
  • United States
  • World
  • Forecast
  • Type 2 Diabetes Development Stages for Pipeline Drugs
  • Top Targets for Pipeline Drug Development Against Type 2 Diabetes

Type ## Diabetes: Competitive Landscape to 2026 Report Code: GDHC##CL Published: March 2018 Healthcare TABLE OF CONTENTS ##.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Sanofi S.A.
  • DEFRONZO RA, ET AL. (2014). NOVEL AGENTS FOR THE TREATMENT OF TYPE 2 DIABETES. DIABETES SPECTRUM; 27: 100-112
  • VAN AMBURGH JA (2015). WHY SELECT EXTENDED-RELEASE METFORMIN? MEDSCAPE MULTISPECIALTY. AVAILABLE FROM: HTTP://WWW.MEDSCAPE.COM/VIEWARTICLE/845753 [ACCESSED ON JUNE 7, 2017]

GENETICS OF TYPE ## DIABETES.

  • Type 2 Diabetes
  • Market Size
  • AstraZeneca PLC
  • Novo Nordisk Group
  • Sanofi S.A.

Semaglutide and ITCA ##’s novel formulations will allow for the expansion of the GLP-## agonist class.

  • Type 2 Diabetes
  • European Union
  • Japan
  • United States
  • Demand

Also discussed are the recent results of the PIONEER studies of oral semaglutide, and the increasing need for cardiovascular data for new drugs that treat type ## diabetes.

  • Antidiabetics
  • Therapy
  • Type 2 Diabetes
  • United States
  • Forecast

Global Type ## Diabetes Epidemiology and Patient Flow Analysis - 2017 ##.

  • Type 2 Diabetes
  • France
  • United States
  • World
  • Forecast

Also discussed are reimbursement and prescribing guidelines in the UK, the recent results of the PIONEER studies of oral semaglutide, and the increasing need for cardiovascular data for new drugs that treat type ## diabetes.

  • Antidiabetics
  • Therapy
  • Type 2 Diabetes
  • United Kingdom
  • Forecast
  • FEATURES OF TYPE 2 DIABETES MELLITUS PATIENTS
  • Sweden Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)

Current Prevalence of Type ## and Type ## diabetes in adults and children in the UK.

  • Type 2 Diabetes
  • East Asia
  • North America
  • Northern Europe
  • Scandinavia

Europe Type ## Diabetes Epidemiology and Patient Flow Analysis - 2017 ##.

  • Type 2 Diabetes
  • Europe
  • France
  • Germany
  • Forecast

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 2 Diabetes
  • France
  • United States
  • Market Shares
  • Market Size
  • TYPE 2 DIABETES DRUGS MARKET IN EMEA
  • GLOBAL TYPE 2 DIABETES DRUGS MARKET

It is indicated for the treatment of type ## and type ## diabetes mellitus.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 2 Diabetes
  • France
  • Germany
  • Market Shares
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Japan
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • United States
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • United Kingdom
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Italy
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Germany
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • France
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Spain
  • Market Size
  • KOL Profile: Dennis Andress, Clinical Trials
  • 8.5.3. KOL PROFILE: GLENN CHERTOW

DIABETES-TRIGGERED KIDNEY DISEASE HAS BEEN OBSERVED TO BE MORE COMMON AMONG TYPE ## DIABETICS; HOWEVER, SINCE THE PATIENT POPULATION FOR TYPE ## DIABETES IS HIGHER, THE NUMBER OF INDIVIDUALS WITH THE LATTER CONDITION SUFFERING FROM CKD IS HIGHER.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Resverlogix Corp.
  • Vifor Pharma

Invokana

8770 10000 7800

Invokana CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Invokana : Diabetic nephropathy ## Invokana : Diabetes type ## LIST OF FIGURES ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Invokana for diabetic nephropathy ## Figure ##: Datamonitor Healthc

  • Type 2 Diabetes
  • European Union
  • Japan
  • United States
  • Demand

Jardiance

8770 10000 7800

Jardiance CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Jardiance : Diabetic nephropathy ## Jardiance : Chronic heart failure (CHF) ## Jardiance : Diabetes type ## LIST OF FIGURES ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Jardiance for diabet

  • Type 2 Diabetes
  • European Union
  • Japan
  • United States
  • Demand

FIGURE ##-##: ACELITY L. P.

  • Type 2 Diabetes
  • World
  • Acelity L.P. Inc.
  • Coloplast Group
  • Derma Sciences, Inc.
  • 4.3 ETIOLOGY AND PATHOPHYSIOLOGY
  • Case Flow Map

PREVALENCE OF TYPE ## AND TYPE ## DIABETES AMONG CHILDREN AND ADOLESCENTS FROM 2001 TO 2009.

  • Type 2 Diabetes
  • Forecast
  • Daiichi Sankyo Company
  • Depomed, Inc.
  • Pfizer Inc.

Farxiga

8770 10000 7800

It is approved for the treatment of type ## diabetes and currently in Phase III trials for the treatment of type ## diabetes, as well as for chronic kidney disease including diabetic nephropathy.

  • Type 2 Diabetes
  • European Union
  • Japan
  • United States
  • Demand

Market Overview Increasing incidence of diabetic nephropathy among diabetic patients The incidence of diabetic nephropathy was observed to be much higher in freshly diagnosed cases of type ## diabetes patients.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • World
  • Social Conditions
  • MM, DIAGNOSED PREVALENCE OF DME IN THE DIAGNOSED DIABETIC RETINOPATHY POPULATION,
  • 5.3 GLOBAL AND HISTORICAL TRENDS

The upsurge in DME prevalence will be driven by the US and ##EU, where it is expected to increase at a CAGR of ##% directly following the increases expected for type ## and type ## diabetes.

  • Type 2 Diabetes
  • Allergan plc
  • Clearside Biomedical, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

Drug Overview: Invokana TABLE OF CONTENTS ## Product Profiles ## Invokana : Diabetic nephropathy ## Invokana : Diabetes type ## LIST OF FIGURES ## Figure ##: Invokana for diabetic nephropathy – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary for Invokana in

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Type 2 Diabetes
  • European Union
  • Japan
  • United States

Drug Analysis: Invokana TABLE OF CONTENTS ## Product Profiles ## Invokana : Diabetic nephropathy ## Invokana : Diabetes type ## LIST OF FIGURES ## Figure ##: Invokana for diabetic nephropathy – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary for Invokana in d

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Type 2 Diabetes
  • European Union
  • Japan
  • United States